share_log
Reuters ·  May 6 08:03
Lyell Immunopharma Inc - on Track to Report Initial Clinical Data From Phase 1 Trial of Lyl845 in Second Half of 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment